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We are pleased to bring you the Special Issue of the Journal
Thyroid Research dedicated to Thyroid Oncology.
The incidence of thyroid cancer has been increasing in
recent decades mainly due to an increase in papillary thyroid
carcinomas (PTCs). Among these, tumors ≤1cm increased
the most. Whether this represents a higher sensitivity to
detect smaller tumors or depends on other factors such as
environmental factors remains unclear [1–3].
According to the World Health Organization (WHO),
papillary thyroid carcinomas measuring 1cm or less are
designated as papillary thyroid microcarcinomas (PTMCs).
Incidentally diagnosed PTMCs are generally indolent
tumors. However, PTMCs detected due to clinically suspect-
ed and histological conﬁrmed lymph node metastases or as-
sociated with extra thyroidal extension may have a more ag-
gressive behavior [4, 5]. Thus, it is inaccurate and misleading
to regard all PTMCs patients as having the same level of risk.
Most studies based their conclusions on clinicopathological
factors. Recently, Kim et al. [6] showed that the gene expres-
sion proﬁles of PTMCs were not diﬀerent from those of
largerPTCsandsuggestedthatPTMCsmayrepresentanear-
lier stage of the same disease.
Diﬀerencesintheformofpresentationbetweenpapillary
microcarcinomas and papillary carcinomas of larger size are
discussed in this issue by C. Zafon et al., who concluded that
patients with a low aggressive proﬁle were signiﬁcantly older
than the remaining patients. This interesting ﬁnding awaits
conﬁrmation by other studies and larger series.
Fine-needle aspiration cytology (FNAC) of thyroid
nodules is highly sensitive in the diagnosis of papillary,
medullary, and anaplastic carcinomas. Distinction between
benign lesions, such as follicular adenoma or nodular
adenomatous goiter, and follicular carcinoma or follicular
variant of papillary carcinoma remains a problem. The ﬁnal
diagnosis depends on histological evaluation.
The study by M. Bonzanini et al. addresses practical
issues related to the existence of diﬀerent FNAC classiﬁ-
cations [7, 8] and was designed to retrospectively analyze
the beneﬁts of subclassifying the “undetermined” cytologic
reports into two categories: “follicular lesion” (FL) and
“atypia of undetermined signiﬁcance” (AUS). Data obtained
on this basis indicate that AUS is associated with higher
malignancy rate than FL. Moreover, the authors provide
data in favor of an integrated analysis of clinical, cytological,
biochemical, and ecographic ﬁndings to improve diagnostic
accuracy.
Young patients with diﬀerentiated thyroid carcinoma
(DTC) represent a particular group. Childhood DTC is
more frequently multicentric and is associated with a more
locally aggressive and more frequent distant disease than its
adult counterpart. Nonetheless, recent series [9], with long
followup, have shown that fewer than 2% of children die
from DTC contrasting to a much higher number of patients
dying from nonthyroid malignancy. Further more, seventy-
threepercentofthosewhodiedfromnonthyroidmalignancy
had received adjuvant radioactive iodine ( 131I) therapy.2 Journal of Thyroid Research
In children, the lungs are almost the sole distant meta-
static site, and pulmonary metastases are nearly always func-
tional [10].
A risk-stratiﬁed approach is probably the best choice to
optimize treatment and reduce risks associated with ther-
apy[11].Tochooseamongtheclassicalriskstratiﬁcationsys-
tems, the most adequate one for young patients is still a
matter of debate. F. Vaisman et al. discuss these and other
points.
Medullary thyroid carcinoma (MTC) is a neuroen-
docrinetumorderivedfromparafollicularcellsofthethyroid
that occurs in both sporadic and hereditary forms. MTC
s p r e a d se a r l yt ol y m p hn o d e sa n di sb o t hc h e m o -a n dr a d i -
oresistant. Early surgery is the only therapeutic approach
potentially curative thus explaining the importance of an
early detection.
Activating mutations of the rearranged during transfec-
tion (RET) proto-oncogene were ﬁrst described in patients
with familial forms in 1993 [12, 13]. Additionally, somatic
RET mutations were identiﬁed in up to 65% of patients with
sporadic MTC [14, 15]. The RET gene is located in chromo-
some 10q11.2 and codes for a tyrosine kinase (TK) receptor.
These molecular advances made possible to deﬁne genotype-
phenotype correlations; the International RET Mutation
ConsortiumandtheAmericanThyroidAssociationprovided
guidelines for the timing of prophylactic surgery based
on genetic analysis [16, 17]. Moreover, promising targeted
therapies have been developed for progressive and advanced
MTC.
Genetic screening became a routine, worldwide, in the
management of MTC patients at a preclinical stage. Results
presented by M. Hedayati et al. in the current issue, in addi-
tion to those previously presented by Alvandi et al. [18], are
illustrative of the mutational proﬁle observed among Iranian
patients with MTC.
Based on the understanding of the altered molecular
pathways underlying MTC, a number of “targeted” therapies
have been developed. K. G´ o m e ze ta l .p r e s e n tac o m p r e h e n -
sive review of the most promising TK inhibitors for the treat-
ment of MTC and draw attention to possible adverse eﬀects
and drug resistance.
Standard treatment of DTC includes surgery, 131Ia n d
thyroid hormone suppressive therapy. 131I, selectively target-
ing thyroid cells, was probably the ﬁrst targeted therapy for
cancer. For those cases refractory to131I and for patients with
local aggressive or metastatic disease, until recently, there
were no eﬀective treatments.
During the last decades, a large body of information has
been generated on the molecular alterations, particularly on
the role of oncogenic kinases involved in thyroid carcinomas.
Based on this information, thyroid became, once more, a
model for the use of new targeted therapies specially the
kinase inhibitors. Interest in this ﬁeld grew, and future holds
promise. The role for combinatory treatments is still not
deﬁned.
Papers by H. Prazeres et al. and S. B. Bales et al. review
genomic changes in thyroid cancer (DTC and MTC) and
discuss how this information might be used to improve
targeted therapies.
Epigenetic mechanisms are likely to play an important
role in thyroid cancers particularly by modulating tumor
progression. Whereas mutations generally alter intracellular
signaling pathways, the epigenetic mechanisms may interfere
with tumor environment as recently shown [19]. In this
issue, O. P. Eze et al. present a thorough revision of this
theme and discuss implications for future therapies designed
to attain diﬀerent pathways.
Clinical trials of TK inhibitors in patients with advanced
thyroid cancer have shown promising preliminary results,
justifying enthusiasm among physicians and expectation
amongpatients.TheFoodandDrugAdministrationrecently
approved Vandetanib for local advanced or metastatic MTC.
Despite the promising results, TK inhibitors have a
broad spectrum of adverse eﬀects. Considering that this class
of therapeutic agents is to be used as chronic treatment,
clinicians responsible for their use need to be familiar with
adverse eﬀects associated with TK inhibitors and prepared
to manage them. M. E. Cabanillas et al. provide us with
a comprehensive revision and practical tips to optimize
treatment and minimize toxicity.
We are grateful to all contributors, reviewers, and the
editorial staﬀ.
Maria Jo˜ ao M. Bugalho
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